A: Empagliflozin (BI 10773), a potent and selective SGLT-2 inhibitor, induces dose-dependent glucosuria in healthier subjects. Clinical Pharm in Drug Dev 2013. doi:10.1002/cpdd.16 [Epub ahead of print]. 11. Cubeddu LX: QT prolongation and fatal arrhythmias: A evaluation of clinical implications and effects of drugs. Am J Ther 2003, 10:452?57. 12. European Medicines Agency: ICH subject E14: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: Step 5: Note for guidance on the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs. 2005. November 2005, CHMP/ICH/2/04. Obtainable from http://ema.europa.eu. Accessed 26 March 2012. 13. van Noord C, Eijgelsheim M, Stricker BH: Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol 2010, 70:16?3. 14. Preis SR, Hwang SJ, Coady S, Pencina MJ, D’Agostino RB Sr, Savage PJ, Levy D, Fox CS: Trends in all-cause and cardiovascular disease mortalityRing et al. Cardiovascular Diabetology 2013, 12:70 http://cardiab/content/12/1/Page 11 of15.16. 17. 18. 19. 20. 21. 22. 23. 24.25.26.27.28.29. 30.31.32. 33.34.35. 36. 37. 38.39. 40. 41.amongst ladies and men with and with no diabetes mellitus within the Framingham Heart Study, 1950 to 2005. Circulation 2009, 119(13):1728?735. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di AE, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, et al: Diabetes mellitus, fasting blood glucose concentration, and danger of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375:2215?222.Ir[dF(CF3)ppy]2(dtbbpy)PF6 supplier DeSouza CV, Fonseca V: Therapeutic targets to lower cardiovascular disease in variety two diabetes.779353-64-9 Purity Nat Rev Drug Discov 2009, 8:361?67. DeSouza CV, Bolli GB, Fonseca V: Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 2010, 33:1389?394. WHO: Planet Wellness Organization Diabetes factsheet. 2011. Accessible from http:// who.int/mediacentre/factsheets/fs312/en/. Accessed 26 March 2012. DeFronzo RA: Overview of newer agents: Exactly where therapy is going. Am J Med 2010, 123:S38 48. Ovalle F: Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes. Clin Ther 2011, 33:393?07. Chanter DO: Much more energy for the cash. Prague: Drug Data Association Cardiac Safety Conference; 2007.PMID:23341580 Ring A, Walter B, Larbalestier A, Chanter D: An efficient cross-over design for thorough QT studies. GMS Med Inform Biom Epidemiol 2010, six:Doc05. Julious SA: Seven beneficial styles. Pharm Stat 2012, 11:24?1. Food and Drug Administration: International conference on harmonisation; guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic prospective for non-antiarrhythmic drugs. Fed Regist 2005, 70:61134?1135. Bloomfield DM, Kost JT, Ghosh K, Hreniuk D, Hickey LA, Guitierrez MJ, Gottesdiener K, Wagner JA: The effect of moxifloxacin on QTc and implications for the style of thorough QT studies. Clin Pharmacol Ther 2008, 84:475?80. Morganroth J, Ilson BE, Shaddinger BC, Dabiri GA, Patel BR, Boyle DA, Sethuraman VS, Montague TH: Evaluation of vardenafil and sildenafil on cardiac repolarization. Am J Cardiol 2004, 93:1378?three. A6. Extramiana F, Maison-Blanche P, Cabanis MJ, Ortemann-Renon C, Beaufils P, Leenhardt A: Clinical assessment of drug-induced QT prolongation in association with heart price changes. Clin Pharmacol Ther 2005, 77:247?58. Demolis JL, Kubitza D, Tenneze L, Funck-Brentano C: Effect of a single oral dose of moxif.